US Pet Care Growth Normalizes to 4%, Favoring CHWY, FRPT, and IDEXX

Core Conclusion

Industry growth is decelerating toward a ~4% normalized rate, below the ~MSD+ consensus. The alpha lies in stock selection: companies with secular capture of vet-driven share, fresh food migration, or diagnostic intensity—CHWY, FRPT, and IDEXX—can compound materially above this lower industry ceiling. Pure-play e-commerce and discretionary-levered specialty retail face the sharpest headwinds.

The Market Underestimates Maturity

Consensus still prices the pet industry as a post-COVID growth compounder. Our AlphaWise survey and economists’ forecasts paint a different picture: ownership rates have reverted to pre-COVID baselines, inflation is structurally elevating ownership cost, and the marginal consumer—18-to-34-year-olds—is pulling back. The 2026 growth estimate of ~3.6% and a 2025–2030 CAGR of ~4.1% both run below historical trend. The market’s embedded growth premium misprices the phase shift from tailwind-driven expansion to wallet-share competition.

Evidence Chain

Structural normalization in ownership and spend per pet. Pet ownership among 18–34-year-olds dropped to ~75%, aligning with the 35–54 cohort for the first time. Intentions to acquire a new pet have weakened among this historically highest-propensity group. Simultaneously, premiumization is moderating as sticky inflation forces trade-offs across household budgets. Industry growth is no longer volume-plus-mix driven; it is increasingly price-only, and price is losing elasticity.

Investment implication: Revenue growth will compress for businesses that depend on household formation (pure-play supplies, general merchandise) unless they have substitution drivers. CHWY’s autoship-based consumables model and FRPT’s modality shift in dog food provide growth that is less correlated with net-new-pet count.

Services outpace products as vet centrality holds. Vet services are projected to compound at ~4.4% versus ~3.9% for products through 2030. Veterinarians remain the most trusted information source (57% preference, up from 53% in 2024). While routine visit volumes have softened, increasing revenue per visit and higher-acuity procedures support resilient topline dynamics. Dispensing share is gradually shifting online, but the vet remains the starting point for diagnostics and therapeutics.

Investment implication: IDEXX benefits from the formula: aging pets + diagnostic penetration + vet clinic consolidation. The placement of analyzers and recurring consumable pull-through is a secular volume driver insulated from discretionary cyclicality. CL, with 3–4% long-term organic sales growth, is a slower but reliable compounder on vet consolidation and lab network density.

Channel shift favors digital integration, not pure-play e-commerce. Online penetration has stabilized, not accelerated. Consumers are gravitating toward one-stop formats, eroding destination-based specialty trips. The tailwind for pure e-commerce players is smaller than consensus models assume.

Investment implication: CHWY’s ~8% 5-year sales CAGR is sustained by sticky subscription relationships and healthcare service adjacency, not by e-commerce penetration lift. FRPT’s LDD+ long-term organic growth is driven by fridge placement and category conversion inside existing retail, a channel-agnostic volume story.

Key Risks

Persistent inflation compounds affordability stress. Cost fatigue disproportionately hits the youngest cohort, which historically drove net-new household formation. A further erosion of adoption intentions would compress the industry’s addressable growth pool more than our already-below-consensus forecast anticipates.

Tariff or supply-chain disruption to fresh and refrigerated supply chains. FRPT’s growth relies on just-in-time production and direct-to-fridge logistics. Any trade-policy shock raising input costs (proteins, packaging) or breaking cold-chain reliability would immediately compress unit economics.

Shift in veterinary channel power. If alternative information sources gain share among younger demographics faster than expected, the vet’s role in product recommendation and dispensing could erode, slowing the secular diagnostic and therapeutic pull-through that underpins IDEXX and CL’s growth algorithms.

Trade Implications

In a ~4% industry, differentiation is selection. Own companies with organic growth drivers independent of pet count and discretionary premiumization: CHWY (recurring share-of-wallet, healthcare extension), FRPT (category conversion, not household growth), and IDEXX (installed-base compounding). Avoid or underwrite cautiously any exposure to destination specialty retail or general merchandise e-commerce reliant on household formation tailwinds that no longer exist.